113512-57-5

Basic information

• Product Name: 2,4-Difluoro-5-nitrophenol
• Synonyms: 2,4-Difluoro-5-nitrophenol;2,4-Difluoro-5-hydroxynitrobenzene;Phenol, 2,4-difluoro-5-nitro-
• CAS NO: 113512-57-5
• Molecular Formula: C₆H₃F₂NO₃
• Molecular Weight: 175
• Mol File: 113512-57-5.mol
• Article Data: 7

Chemical Properties

• Melting Point: 112-120℃
• Boiling Point: 160-162 °C(Press: 24 Torr)
• Appearance: /
• Density: 1.619±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 6.81±0.24(Predicted)
• Water Solubility: Sparingly soluble in water but readily soluble in organic solvents.
• CAS DataBase Reference: 2,4-Difluoro-5-nitrophenol(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Difluoro-5-nitrophenol(113512-57-5)
• EPA Substance Registry System: 2,4-Difluoro-5-nitrophenol(113512-57-5)

Safety Data

• Hazardous Substances Data: 113512-57-5(Hazardous Substances Data)

Usage

Uses

2,4-Difluoro-5-nitrophenol may be used in chemical synthesis.

Upstream product

• 126-33-0 sulfolane 
• 7664-93-9 sulfuric acid 
• 152169-43-2 2,4-difluorophenyl ethyl carbonate 
• 367-27-1 2,4-difluorophenol 

Downstream Products

• 179011-39-3 1,5-difluoro-2-methoxy-4-nitrobenzene 

Relevant articles and documents

METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES

Compounds of the present invention find utility in the treatment of hyperproliferative diseases, mammalian cancers and especially human cancers including but not limited to malignant, melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, cervical carcinomas, metastasis of primary tumor sites secondary sites, myeloproliferative diseases, chronic myelogenous leukemia, acute lymphocytic leukemia, papillary thyroid carcinoma, non small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, thyroid cancer, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, i.e. diabetic retinopathy and age-related macular degeneration, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, human inflammation, rheumatoid spondylitis, ostero-arthritis, asthma, gouty arthritis, sepsis, septic shock, endotoxic shock, Gram-negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, stroke, reperfusion injury, neural trauma, neural ischemia, psoriasis, restenosis, chronic obstructive pulmonary disease, bone resorptive diseases, graft-versus-host reaction, Crohn's disease, ulcerative colitis, inflammatory bowel disease, pyresis, and combinations thereof, a disease caused by c-ABL kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, c-KIT kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, VEGFR kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, PDGFR kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, FLT-3 kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, TIE-2 kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, TRK kinases, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, c-MET kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, or a disease caused by a HER kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof.

Synthesis of an ethyl 6-amino-3,5-difluorosalicylate derivative by sequential regioselective directed ortho- metalation; a practical synthesis of 4',5-Diamino-3',6,8-trifluoroflavone, a potent antitumor agent

The multigram scale synthesis of 4',5-diamino-3'6,8-trifluoroflavone, a potent antitumor agent, is described in which regioselective introduction of a carbonyl group into the ortho-position to the amide group of 2-[2,4-difluoro-5-(pivaloylamino)phenyoxy]tetrahydropyran is achieved by using sequential direct ortho-metalations as the key step.

5-aminoflavone derivatives

5-Aminoflavone derivatives represented by the formula (I): STR1 wherein R1, R2, R3 and R4 are the same or different and represent hydrogen, substituted or unsubstituted lower alkyl, lower alkenyl, halogen-substi